By Blake Brittain (Reuters) -British pharmaceutical giant GlaxoSmithKline and rival Pfizer have agreed to end a lawsuit that ...

GSK has continued to flesh out its neuroscience strategy with a 2 billion pound sterling ($2.5 billion) deal to use a South ...

The pharma giant is wagering potentially billions of dollars on technology from ABL Bio that’s designed to get drugs across ...

NEW YORK CITY, NY / ACCESS Newswire / April 7, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, ...

Fear and panic returned to the world’s stock markets today after Donald Trump’s swingeing new “Liberation Day” tariffs came ...

As the respiratory syncytial virus (RSV) vaccine field grapples with a significantly reduced market size thanks to regulatory ...

In a jobs market marred by a hiring slowdown, Staffline (STAF) appears to be bucking the trend. Unlike its larger peers, the Aim-listed blue-collar recruiter grew revenue, underlying operating profits ...

In 2018, the company struck a four-year collaboration deal with pharmaceutical giant GSK “to gather insights and discover ...

GSK) stands against the other best ADR stocks. American Depositary Receipts (ADR) are US-listed securities that represent ...

Stock analysts at Zacks Research upped their FY2027 earnings per share estimates for GSK in a report issued on Tuesday, March ...

GSK and Pfizer said in the filing, opens new tab that they would dismiss the case with prejudice, which means it cannot be refiled. Spokespeople for the companies did not immediately respond to ...